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Invariance-based analysis of cancer chemotherapy?
Rachid Riah1, Mirko Fiacchini1 and Mazen Alamir1
Abstract— In this paper, chemotherapy of cancer is studied.
The model chosen to simulate the behaviour of the cancer is
based on the normal and the tumor cells evolution. Aggressive
chemotherapy leading to tumor contraction must respect the
constraint on the patient health, which is the lower admissible
bound of the normal cells. The properties of positively invariant
set are employed. The domains of attraction, representing all
the initial states of patients which could be brought back to
the healthy state by respecting the constraint on the patient
health, are determined using set theory tools. The domains of
attraction corresponding to different chemotherapy profiles can
be characterized with this method.
Kaywords: Cancer chemotherapy, Invariance, Set theory.
I. INTRODUCTION
Cancer is a dangerous disease that kills every year thousands
of people in the world. Thus, several scientific researchers
and doctors have been attracted to work on this topic, in
order to help the patients who suffer from this disease.
In the literature, several mathematical models to stimulate
the evolution of the cancer cells have appeared in the last
decades, some of them are based on the evolution of the
different cells, see [1], [7], [12], [17]. Such models may
incorporate the effect of external drugs on the evolution of
the cancer, as chemotherapy and immunotherapy drug or
their combination. In the recent years, mathematical models
of cancer have been widely used also for control-based
tumoral therapy design, applying optimal control [6], [14],
or feedback control, see [2], [5].
Our work in this paper is based on the model inspired by the
work of [1], [17]. It represents the evolution of normal and
tumor cells, taking into account the effect of chemotherapy
drug. In [1], this model is used to represent the evolution
of acute myeloblastic leukemia (AML) and in [17] it has
been used to simulate the cancer evolution. The normal cells
represent a part of the innate immune system of the human
body and can be interpreted as the aggregation of NK cells,
CD8+ cells and a circulating lymphocytes (or white blood
cells) as defined in [5].
In the literature, there are two important categories of
analysis, reachability analysis, which computes the set of
reachable states when the initial state, input, and parameters
are uncertain [16], and the viability kernel is the set of
initial states for which there exists an input such that the
system respects the state constraint for all time. Typically,
the viability kernel is much harder to compute [20], and in
this paper, our approach is substantially based on techniques
and methods from set theory and invariance for control. The
importance of invariant sets in control is due to stability and
robustness implicit properties of these regions of the state
space. Many results regarding invariance and related topics
have been provided in literature: see, for instance, the notable
pioneering contribution [3], the works [11], [13], concerning
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the maximal invariant set, and [18] regarding the minimal
one. The problem of obtaining invariant sets for discrete-
time nonlinear systems is dealt with using ellipsoids in [15]
and polytopes in [9]. A recent monograph on invariance and
set-theory in control is [4].
The main objective of this paper is to determine the maximal
invariant polyhedral set that represents all states of patients
that could be forced to converge to the desired healthy states,
applying a chemotherapy drug administration strategy. The
desired set is defined to be the set for which the number of
tumor cells is close to zero and the normal cells higher then
the minimal admitted level. A minimal level is imposed as
a health condition. This maximal set represents the domain
of attraction of the cancer system.
As is proved in [17] that the strategy of aggressive
chemotherapy is the best technique to eradicate all the
cancer cells, in this preliminary work, the control inputs
are considered to take maximum chemotherapy drugs or no
chemotherapy drugs.
A comparative study between several drug strategies is also
provided. The characterization of the all domains of attrac-
tion for each drug control profile is given, and the suitable
strategy for each patients can be inferred by analyzing the
different domains of attraction.
The paper is organized as follows. In Section II, the mathe-
matical model of cancer is introduced and the problem state-
ment is given. In Section III, the properties and numerical
methods related to the positively invariant sets are given.
The analysis of an appropriate drug administration strategy,
and the comparison among different therapeutic profiles are
given in Section IV. Section V finishes the paper with some
conclusions and future works.
Notation: Given n ∈ N, define Nn = {x ∈ N : 1 ≤ x ≤ n}.
Given a matrix A ∈ Rn×m, Ai with i ∈ Nn denotes its i-th
row, Ai,j with i ∈ Nn and j ∈ Nm denotes the value that
corresponds to the position in the matrix A defined by the
i-th row and the j-th column.
II. MATHEMATICAL CANCER MODEL
Our main objective is to provide an analytical tool to the
biologists for inferring which chemotherapy profile can lead
to substantial reduction of the tumor while maintaining
a patient health indicator above a threshold. The suitable
therapeutic profile should be function of the initial state of
the tumor. Thus, the control goal is to steer the tumor at
an admissible size at the end of the therapy, by holding the
normal cells above the admitted level which is representative
of an healthy condition of the patient.
We consider the mathematical model used in [1], [17] that
models the interaction between tumoral and normal cells and
the effect of chemotherapy drug. This low dimensional model
has been used by many researches in the past to reproduce
and simulate the cancer brain dynamic. The two dynamics
represented in this model are the evolution of the tumor cell
populations and the normal cell populations. The interactions
between them and the effect of chemotherapy drugs are taken
account in this model. The model is based on the following
assumptions, taken from [17]:
1) The growth dynamics of both tumor and normal cell
populations are the same anywhere in the body (i.e. all
cells populations are homogeneous).
2) The tumor and normal cells populations follow a
process of Gompertizian growth.
3) The chemotherapy drug kills both tumor and normal
cells and affects the normal more than the tumor cells.
4) The tumor cells exhibit a negative and inhibiting effect
on the growth and development of the normal cells.
5) The drug spreads instantaneously within the body (i.e.
the drug amount within the body is proportional to the
drug infusion rate).
The resulting model, based on the above assumptions, is
defined as follows:
L˙ = αL ln
θL
L
−Π1(c)L, L(0) = L0,
N˙ = βN ln
θN
N
− Ξ(L)N −Π2(c)N, N(0) = N0.
(1)
This model involves 2 states and 1 control input. All variables
and parameters are given hereafter:
• L and N are the tumor and the normal cell population
respectively,
• α is the tumor growth rate, β is the normal growth rate,
• θL is the greatest size of the tumor cell population, θN
is the normal size of the normal cell population,
• −Ξ(L)N represents the negative effect of the tumor on
the normal cells,
• c stands for the concentration of the chemotherapy drug,
• Π1(c) and Π2(c) are the loss functions for both popu-
lation due to chemotherapy effect.
As in the work [17], we adopt in the sequel the following
approximations:
1) the function Ξ(L) is taken to be linear as in [1], [17]
(i.e. Ξ(L) = γL, where γ is a given parameter);
2) we consider that the loss function Π1(c) as a control
input taking into account the saturation phenomena
(i.e, Π1(c) = u);
3) we also assume that Π2(c) = lΠ1(c), l is a given
parameter (i.e. Π2(c) = lu).
Thus, the resulting model becomes:
L˙ = αL ln
θL
L
− uL, L(0) = L0,
N˙ = βN ln
θN
N
− γLN − luN, N(0) = N0.
(2)
Physically the normal cells growth faster then the tumor ones.
In view of this, we assume that the rate growth of normal
cells β is bigger then the rate growth of tumor cells α, see
[1], [17], that is β > α. Notice that the nonlinear model
(2) involves np = 6 parameters. The consistent values for
these parameters are inferred from the scientific literature
and summarized in Table 1, see [1], [17].
A. Equilibrium points and observations
Notice that the first equation in Eq.(2) has one zero at the
tumor free equilibrium at LE = 0 and several possible non
zero tumor equilibria. The tumor free equilibrium for the
system is given by (LE , NE) = (0, θN ). Let E0 represents
the point (0, θN ). To determine the equilibria in the case
where LE 6= 0, we have to solve the Eq.(2) and find
the non zero tumor equilibria. This point is (LE , NE) =
(θL, θNe
− γθLβ ) in absence of chemotherapy drug. According
to the Gompertzian dynamics of the tumor cells, the tumor
free equilibrium is unstable, while the high tumor equilib-
rium is stable. This means that if the treatment is stopped,
the system returns inevitably to the hight tumor state.
According to the model, when no cancer cells are present
in the body, the normal cells grow monotonically and tend
toward its asymptotic bound. Tumor cells increase also
monotonically with time, in the presence of normal cells. It
is asserted that the two cell populations follow a process of
Gompertzian growth. Thus, when the cancer is large enough
to affect the normal cells, these last cells tend to decrease
dramatically to an abnormally low level. This is due to the
negative effects exercised by the tumor cells on the normal
ones. However, the tumor cells continue to increase to his
bound limit and the design of chemotherapy is very complex
and should therefore incorporate the aim of slowing down
considerably the growth of the tumor cells and removing the
inhibition that they exercise over the normal cells [1], [17].
B. Discrete-time model for analysis
First, introducing the change of variables x1 = ln θLL and
x2 = ln
θN
N , the equivalent system is{
x˙1 = −αx1 + u, x1(0) = x10,
x˙2 = −βx2 + γθLe−x1 + lu, x2(0) = x20, (3)
where x10 and x20 are the initial conditions. The constraints
0 ≤ u ≤ umax and x2 ≤ x2max are considered, where umax
is the maximal control input and x2max is the maximal value
of x2. Considering that Nmin is the minimal admitted level
of the normal cells, then x2max = ln
θN
Nmin
. This change of
variables reduces the degree of nonlinearity of the system
(2) and permits to better exploit this model.
Finally, the discrete-time system modelling the cancer evo-
lution is obtained by sampling the continuous system (3),
with Euler discretization method and sampling time of Ts =
0.5day, opted using Matlab simulations. It results in x
+
1 = (1− Tsα)x1 + Tsu = f1(x, u),
x+2 = (1− Tsβ)x2 + TsγθLe−x1 + Tslu,= f2(x, u),
x1(0) = x10, x2(0) = x20,
(4)
which is more suitable to apply the iterative methods for
invariant set computation.
As shown in the literature, the strategy of intensive
chemotherapy is the best one to eradicate the cancer cells,
[17]. However, this strategy is not efficient for all patients,
and in some cases it can worsen the patient’s situation by
not respecting the health condition. In this paper, our main
goal is to determine the domains of attraction of the cancer
system related to different chemotherapy profiles. Given a
therapeutic strategy, the domain represents all the states of
the patients for which the therapy leads to a substantial
regression of the tumor size by preventing the health measure
to reach values dangerous for the patient. Based on those do-
mains of attraction, the analysis of the more appropriate drug
param value param value
α 3.96× 10−3 day−1 β 3.33× 10−2 day−1
θN 1.4× 1012 cells θL 3× 1012 cells
γ 5× 10−6 (cells.day)−1 l 10−2
TABLE I: Parameters of the dynamic model (2).
administration strategy can be inferred, and the comparison
between different therapeutic profiles can be performed.
The methods proposed are substantially based on the prop-
erties of positively invariant sets that will be introduced in
the sequel.
III. INVARIANCE AND DOMAIN OF ATTRACTION
The properties of positively invariant sets have been used in
the recent years for characterizing the domain of attraction
of dynamical systems and are particularly suitable for con-
strained and robust control. The main aim of this paper is
to compute the set of initial values of the number of normal
and tumoral cells for which an admissible therapeutic profile
exists. This problem consists in practice in obtaining the
maximal contractive invariant convex set as an estimation
of the domain of attraction for the system (4). Let us now
introduce some useful tools to deal with convex closed sets
and difference inclusions systems. Consider the difference
inclusions system
x+ ∈ F(x) (5)
where x ∈ X ⊆ Rn is the state, x+ is the successor and F(·)
is a set valued map on Rn, that is F(x) represents a function
which relates a set to every point x ∈ Rn, i.e. F(x) ⊆ Rn
for all x ∈ Rn. The set X is intended to be, hereafter, the
set of state constraints.
Remark 1: The interest of difference inclusions systems
relies in the fact that they can be used to represent controlled
and/or uncertain systems and also to approximate nonlinear
systems x+ = f(x), i.e. such that f(x) ∈ F(x) for all x ∈
X . In particular, in this paper we use difference inclusions
to bound the dynamics of the nonlinear system (4) for u = 0
and u = umax, and to obtain invariant sets and domain of
attraction for the former, that are invariant and domain also
for the latter. Surprisingly, the conservatism often introduced
when approximating a nonlinear system with a difference
inclusions one can be made arbitrarily small for the case
under analysis. Thus the exact domain of attraction can be
approximated with the desired precision with the present
method.
An important tool to deal with convex closed sets is the
support function, it is defined hereafter.
Definition 1: Given a set Ω ⊆ Rn, the support function of
Ω evaluated at η ∈ Rn is φΩ(η) = supx∈Ω ηTx.
Geometrically, the support function of Ω at η is the signed
”distance” of the point of the closure of Ω further from the
origin, along the direction η. See [19] for some properties
of support functions. Using the support function is helpful
to transform a set-inclusion condition in terms of linear
inequalities, see [19] for instance. From the definition of the
support function, we get this property.
Property 1: Given two closed, convex sets Ω ⊆ Rn and Γ ⊆
Rn, then x ∈ Ω if and only if ηTx ≤ φΩ(η) for all η ∈ Rn,
and Γ ⊆ Ω if and only if φΓ(η) ≤ φΩ(η), for all η ∈ Rn.
Before giving the definition of invariance, let us introduce
this assumption.
Assumption 1: Assume that the set valued map F determin-
ing the system dynamics (5) is such that F(x) is compact and
convex for all x ∈ Rn and, for every η ∈ Rn, the function
F (x, η) : Rn × Rn −→ R defined as
F (x, η) = φF(x)(η) = sup
z∈F(x)
ηT z, (6)
is convex with respect to x on X .
Thus, in practice, F (x, η) is the support function of set F(x)
evaluated at η ∈ Rn and then
F(x) = {z ∈ Rn : ηT z ≤ F(x, η), ∀η ∈ Rn}, (7)
and it is convex in x. The dynamical systems (5) for
which Assumption 1 holds are tightly related to the Convex
Difference Inclusions (CDI) systems defined in [8], [10].
Remark 2: Notice that, with respect to the CDI systems,
no assumption on the value of F (0, η) is done here. This
because, while the CDI systems defined in [8], [10] are
employed for characterizing invariance and contractivity with
respect to the origin, in this paper, the convergence of the
CDI system is towards the infinity along an asymptote.
Now, we recall the standard definitions of invariance set for
the generic nonlinear system, adapted here for the case of
potentially unbounded sets that do not necessarily contain
the origin and set valued maps.
Definition 2 ([4]): The closed convex set Ω ⊆ Rn is an
invariant set for the system x+ = f(x) if f(x) ∈ Ω, for all
x ∈ Ω, it is invariant for the difference inclusions system (5)
if F(x) ⊆ Ω, for all x ∈ Ω.
Every trajectory starting in an invariant Ω remains in it. For
the difference inclusions system (5), the invariance of Ω ⊆
X , can be given, as usual, in terms of the one-step backward
operator, defined below.
Definition 3: Let Assumptions 1 hold for the set valued
map F(·) determining the dynamic system (5). The one-step
operator is defined as
Q(Ω) = {x ∈ X : F(x) ⊆ Ω}, (8)
for all Ω ⊆ X .
Hence, the one-step operator associates to every set Ω the set
of points that are mapped inside Ω through F(·). Thus, by
definition, a closed convex set Ω ⊆ X is invariant if and only
if Ω ⊆ Q(Ω) and the one-step operator can be used to check
invariance and to compute increasing sequences of nested
invariant sets, as for linear or nonlinear systems. Indeed,
Algorithm 1, standard for generating increasing invariant
approximations of the domain of attraction, see [4], can be
applied also in this context. Thus, Ωk are invariant and
Algorithm 1 Increasing sequence of invariant sets for (5)
Input: Initial convex closed invariant set Ω0 ⊆ X .
1: for k ∈ NN do
2: Compute Ωk+1 = Q(Ωk) ∩X
3: if Ωk+1 = Ωk then Ωmax = Ωk return
4: end if
5: end for
converges to the domain of attraction for the system (5),
and hence for all nonlinear systems approximated by (5).
Finally, being our objective to have a sequence of Ωk that
are polyhedral, we introduce the following results, proved in
[8], which is functional for this purpose.
Proposition 1: Given the set-valued map F(x) determining
the system dynamics (5) and the state constraint set X . Given
a polytope Ω = {x ∈ Rn : Hx ≤ h}, with H ∈ Rnh×n, the
one-step operator is
Q(Ω) = {x ∈ X : F (x,HiT ) ≤ hi, ∀i ∈ Nnh}. (9)
Notice that, as proved in [8] for general convex closed sets,
for every polytopic Ω, the set Q(Ω) is closed and convex.
Moreover, if F (·, η) are piecewise affine functions of x, then
Q(Ω) is a polyhedron, that is the intersection of a finite
number of halfspaces, for every polytopic (or polyhedral) Ω.
Remark 3: The problem of boundedness of the sets Ωk can
be addressed, for computational aims, by adding appropriate
fictitious constraints on X such that it results to be bounded.
This approach has been used to obtain the domains of
attraction illustrated in the following.
In fact, Algorithm 1 is efficient and scalable to provide
the maximal invariant set for all high-dimensional nonlinear
systems for which the related one-step operator given by (9)
is not hardly computable. Once the set of constraint states X
and the initial invariant set Ω0 are selected, Algorithm 1 is
fully automatic and no parameters are needed to be selected.
This operator is employed to find the region of stability of
the system which represents the evolution of the cancer, for
the given profile of the chemotherapy drug.
IV. CANCER CHEMOTHERAPY ANALYSIS
In order to use the Algorithm 1 to find the maximal invariant
set for the system (4), reproducing the evolution of the
cancer, the one-step operator defined in Proposition 1 is
employed. Once the maximal invariant set found in this
domain, it will be translated to the tumor-normal cells
domain.
Remark 4: From many results in literature, see for instance
[17], one can infer that the most efficient drug profiles are
given by sequences of periods of maximal delivery, i.e.
u = umax, and periods of no chemotherapy drug perfusion,
i.e. u = 0. Hence, in this paper, the profiles composed by
maximal or null drug deliverance are considered. Neverthe-
less, the method proposed can be applied directly for variable
values of u, it is sufficient to focus on control invariance sets
in spite of invariant ones.
To determine the one-step operator for the two dynamics,
with u = umax and u = 0, it necessary to determine the
bounding functions Fu(x, η) for all η ∈ R2, convex with
respect to x and such that the related set valued maps
Fu(x) = {z ∈ Rn : ηT z ≤ Fu(x, η), ∀η ∈ Rn},
as (7), satisfies f(x, u) ∈ Fu(x), with f(x, u) in (4), for
every x ∈ X and every u ∈ [0, umax]. From Property
1, these functions Fu(x, η) must be convex and such that
ηT f(x, u) ≤ Fu(x, η), for every η ∈ Rn. Moreover, since
the nonlinearity involves only f2(x, u) then the bounding
functions of ηT f(x, u) are related only to η2, since the
dynamics of x1 is linear. A possible choice is
• if η2 ≥ 0: Fu(x, η) = ηT f(x, u),
since Fu(x, η) is already convex in this case;
• if η2 < 0:
Fu(x, η) = η1f1(x, u) + η2
(
(1− Tsβ)x2
+TsγθL(ax1 + b) + Tslu
)
,
(10)
with a and b such that (ax1 + b) ≤ e−x1 , obtained for
instance as the tangent to the graph of e−x1 at one point
and Ts is the sampling time;
for all η ∈ R2.
Nevertheless, we are interested in convex piecewise affine
bounding functions for computational purposes. For this it
is sufficient to replace e−x1 with a convex piecewise affine
upper bound, which is easily obtainable, for the case of
η2 ≥ 0. In fact, it is sufficient to choose a set of p ∈ N
parameters ci ∈ R, di ∈ R, with i ∈ Np, such that,
e−x1 ≤ maxi∈Np{cix1 + di}, for all x1 ∈ R. To obtain
those parameters, it is sufficient to define zi with i ∈ Np+1
such that zi < zi+1 and then
ci =
e−zi+1 − e−zi
zi+1 − zi , di =
zi+1e
−zi − zie−zi+1
zi+1 − zi ,
is the affine function such that e−x1 ≤ cix1 + di for every
x1 ∈ [zi, zi+1] and e−zi = cizi + di for all i ∈ Np, see
Figure 1.
Remark 5: Notice that, in order to increase the precision,
the number of parameters p can be taken as big as desired.
Hence, arbitrary precision can be attained.
Concerning, the case of η2 < 0, no modification is required
with respect to (10), being this already piecewise affine,
affine in fact. Then, we obtain
• if η2 ≥ 0:
Fu(x, η) = η1f1(x, u) + η2
(
(1− Tsβ)x2
+TsγθL maxi∈Np{cix1 + di}+ Tslu
)
,
(11)
• if η2 < 0: Fu(x, η) as in (10).
Figure 1 shows the convex upper bound and the concave
lower bound of e−x1 implicitly used to determine Fu(x, η).
Notice that Fu(x, η) is a convex upper bound of ηT f(x, u),
for all x ∈ X , η ∈ Rn and u ∈ [0, umax].
Remark 6: Since in this application the sequence of poly-
topes generated have never a facet determined by Hi such
that Hi,2 < 0 (except the trivial constraints x2 ≤ 0), then the
lower bound of e−x1 is never employed. This would mean
that the sequence of polytopes obtained and the domain of
attraction are affected only by the mismatches between e−x1
and the piecewise function maxi∈Np{cix1 + di}, mismatch
that can be done arbitrarily small, as notice in Remark 5.
Hence, the desired precision can be achieved by employing
sufficiently close piecewise approximations of e−x1 .
Therefore, given a polytope Ω = {x ∈ R2 : Hx ≤ h} with
H ∈ Rnh,n, and using the upper bound found above and the
consideration in Remark 6, then one-step operator defined in
the Proposition 1 is
Qu(Ω) = {x ∈ R2 : ∀i ∈ Nnh , ∀j ∈ Np,
Hi,1f1(x, u) +Hi,2
(
(1− Tsβ)x2 + TsγθLcjx1
)
≤ hi −Hi,2Tslu−Hi,2TsγθLdj},
(12)
for every u ∈ [0, umax]. Once this operator is defined, for
every given chemotherapy control profile the related one-
step operator can be determined by composing (12). For
instance, the one-step operator for the profile given by one
sampling period of full drug injection and two period of null
chemotherapy is Q[umax, 0, 0] = Qumax(Q0(Q0(Ω))).
Hence, given a chosen drug delivery profile and an initial
invariant polyhedral set for this profile, the Algorithm 1
can be applied to generate an increasing sequence of nested
invariant sets converging to the exact domain of attraction
for that particular therapy.
Definition 4: The set of healthy states is defined to be all the
states of a patients such that the number of a tumor cells is
small enough and the number of normal cells is higher then
the minimal admitted level. Such set, mapped in the space
of x, is the set with x1 big enough and x2 ≤ x2max.
Remark 7: Notice that, the initial invariant polyhedral set
Ω0, which is required to start the recursive procedure, is
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Fig. 1: Bounds of the exponential function.
taken as a set of healthy states. This initial set has been
proved to be invariant for the chemotherapy profiles consid-
ered by proving that the related one-step operator provides
a set containing Ω0, condition equivalent to invariance.
A. Aggressive chemotherapy
The first contribution in this paper leads to determine the
maximal domain of attraction of the cancer system, which
represents all the initial conditions for different patients
affected by cancer, that we can bring to a set of healthy
states applying an aggressive chemotherapy.
Definition 5: An aggressive chemotherapy is defined to be
a therapy that apply heavy doses of chemotherapy drug, i.e.
u(k) = umax for every k ∈ N.
In this work, we assume that the number of a minimal
admitted level of normal cells is Nmin = 4.2826 105cells,
which gives with the change of variable that x2max =
15. This level is chosen approximately in order to better
show our contribution using simulation. Thus, for clinician
experiments the exact value must be employed.
Now, applying the standard recursion starting from the initial
invariant set, one gets a sequence of invariant sets that
converges to the maximal invariant set for the system (4).
Notice that, the same set can be obtained by starting the
Algorithm 1 from the set of constraint X .
Figure 2 shows the sequences of sets that converge to the
exact domain of attraction of the system (4) (except for the
piecewise approximation) in bold line and shows that the
trajectories of the system with initial states at the vertices of
the maximal invariant set converge to the set of healthy states,
eradicating the cancer cells without violating the constraint
on the patient’s health. Theses sets are obtained starting with
the initial invariant set. Recall that for every Ωk, the set Ωk+1
contains all states that will be mapped in Ωk in one step using
one heavy dose of drug.
Figure 3 represents the maximal domain of attraction of
the cancer system in the space of N and L. Notice that,
the trajectories of the continuous-time nonlinear system (2)
starting from the vertices of the maximal domain of attraction
converge toward the set of healthy states.
This domain of attraction represents, with arbitrary precision,
the exact set of all the initial patient states that can be cured
using aggressive chemotherapy. Thus, given the initial state
of a patient, one could infer on the efficacy of the aggressive
chemotherapy, on the amount of drug to deliver and on the
therapy length.
Fig. 2: Maximal invariant set (in black bold line), sequences of polytopes
(in black fine lines) and trajectories (in red line) starting from the vertices
of the maximal invariant set, for the system (4). The admitted level of x2 is
equivalent to the admitted level of the normal cells, which is 4.2826× 105
cells. The chemotherapy drugs u(k), ∀k ∈ N are taken equal to umax.
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Fig. 3: Maximal domain of attraction of cancer system 2 (in bold black
line) and trajectories (in red line) starting from the vertices of the maximal
domain of attraction. The admitted level of the normal cell population is
4.2826×105 cells. The chemotherapy drugs u(k),∀k ∈ N are taken equal
to umax.
B. Comparison between therapeutic profiles
In order to analyse and compare the domain of attraction for
an appropriate drug administration strategy, that might be
defined a priori by a doctor, three profiles of chemotherapy
drugs are taken into account, which are
• Control profile 1: Heavy doses of drugs are applied all
the time.
• Control profile 2: Heavy doses of drugs are applied for
3 days then no doses are applied for 3 days.
• Control profile 3: Heavy doses of drugs are applied for
1 days then no doses are applied for 1 days.
Figure 4 shows the three domains of attraction of tumor
model given by (2). Thus, depending on the control profile
adopted, a specific maximal invariant set is determined. By
analyzing the different domains, one can notice that there are
initial conditions that cannot be cured by the control profile 3,
whereas they can be healed by applying the control profile 2.
Notice that both profiles 2 and 3 have the same drug delivery
rate, i.e. 0.5umax/day. Therefore, it is beneficial to attack
the cancer cells for long period then release, than for small
period.
In Figure 5, a test of invariance for the control profile 3 is
presented. As it can be seen in this figure, the boundary states
of this set are all states evolve inside the set by applying
heavy doses in the first two steps, and then, when no drug
is applied, they are mapped to the boundary of the set. This
is the behavior that one should expect from the maximal
invariant set, that is by the domain of attraction.
2 2.5 3 3.5 4 4.5 5 5.5 6 6.5
5
6
7
8
9
10
11
12
Log10 L
Lo
g 1
0 
N
Controle profile N°1 
Controle profile N°2 
Controle profile N°3 
Fig. 4: Maximal domains of attraction (in bold lines) for cancer system, for
control profiles 1, 2 and 3. The admitted level of the normal cell population
is 4.2826× 105 cells.
Fig. 5: Maximal domain of attraction for cancer system (in bold line),
applying control profile 3 and trajectories (in fine and dashed lines). The
admitted level of the normal cell population is 4.2826× 105 cells.
Now, let us consider and compare the two following profiles
• Control profile 4: No doses of drugs are applied for
2 days then heavy doses are applied for 2 days.
• Control profile 5: Heavy doses of drugs are applied for
2 days then no doses are applied for 2 days.
Figure 6 proves that the set of initial states that can be
healed by the control profile 4 is far smaller than the one
related to those cured by profile 5. Noticing that profile 4
is analogous to apply profile 5 after two days of no drug
perfusion, one can deduce the reasonable conclusion that
delays on the application of a given therapy could undermine
substantially its efficiency. This conclusion is in line with the
recognized importance of screening and the crucial benefit of
early detection of the tumor. From Figures 4, 6, we can see
that the aggressive chemotherapy has the greatest domain of
attraction among the therapies analyzed here.
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Fig. 6: Maximal domains of attraction for cancer system (in bold lines), for
control profiles 1, 4 and 5. The admitted level of the normal cell population
is 4.2826× 105 cells.
In Figure 7, all the domains for each control profile are
showed together. Using this mapping, the appropriate drug
strategy can be chosen according to the state of the patient,
to the amount of drug to deliver or other constraints.
V. CONCLUSION
In this paper, the techniques for computing the domain of
attraction for nonlinear systems are applied to determine
which are the states of tumor patients that can be successfully
cured. The efficiency of different therapeutic profiles can
also be inferred by comparing the different domains of
attraction. Many directions of future work are open by this
preliminary work: control input with all possible value, not
only maximum control input or no control input could be
considered, the inherent presence of modelling uncertainties,
which could also integrate the sampling errors, should be
Fig. 7: Maximal invariant sets (in bold line) for the system (4) for control
profiles 1, 2 , 3, 4 and 5. The admitted level of x2 is equivalent to the
admitted level of the normal cells, which is 4.2826× 105 cells.
taken into account; more complex therapy profiles could
be considered; alternative modelling frameworks could be
employed, for instance.
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